BACKGROUND: We previously reported results of the phase 2, multicenter PINNACLE study, which confirmed the substantial single-agent activity of bortezomib in patients with relapsed or refractory mantle cell lymphoma (MCL). MATERIALS AND METHODS: We report updated time-to-event data, in all patients and by response to treatment, after extended follow-up (median 26.4 months). RESULTS: Median time to progression (TTP) was 6.7 months. Median time to next therapy (TTNT) was 7.4 months. Median overall survival (OS) was 23.5 months. In responding patients, median TTP was 12.4 months, median duration of response (DOR) was 9.2 months, median TTNT was 14.3 months, and median OS was 35.4 months. Patients achieving complete response had heterogeneous disease characteristics; among these patients, median TTP and DOR were not reached, and median OS was 36.0 months. One-year survival rate was 69% overall and 91% in responding patients. Median OS from diagnosis was 61.1 months, after median follow-up of 63.7 months. Activity was seen in patients with refractory disease and patients relapsing following high-intensity treatment. Toxicity was generally manageable. CONCLUSIONS: Single-agent bortezomib is associated with lengthy responses and notable survival in patients with relapsed or refractory MCL, with considerable TTP and TTNT in responding patients, suggesting substantial clinical benefit.
BACKGROUND: We previously reported results of the phase 2, multicenter PINNACLE study, which confirmed the substantial single-agent activity of bortezomib in patients with relapsed or refractory mantle cell lymphoma (MCL). MATERIALS AND METHODS: We report updated time-to-event data, in all patients and by response to treatment, after extended follow-up (median 26.4 months). RESULTS: Median time to progression (TTP) was 6.7 months. Median time to next therapy (TTNT) was 7.4 months. Median overall survival (OS) was 23.5 months. In responding patients, median TTP was 12.4 months, median duration of response (DOR) was 9.2 months, median TTNT was 14.3 months, and median OS was 35.4 months. Patients achieving complete response had heterogeneous disease characteristics; among these patients, median TTP and DOR were not reached, and median OS was 36.0 months. One-year survival rate was 69% overall and 91% in responding patients. Median OS from diagnosis was 61.1 months, after median follow-up of 63.7 months. Activity was seen in patients with refractory disease and patients relapsing following high-intensity treatment. Toxicity was generally manageable. CONCLUSIONS: Single-agent bortezomib is associated with lengthy responses and notable survival in patients with relapsed or refractory MCL, with considerable TTP and TTNT in responding patients, suggesting substantial clinical benefit.
Authors: B D Cheson; S J Horning; B Coiffier; M A Shipp; R I Fisher; J M Connors; T A Lister; J Vose; A Grillo-López; A Hagenbeek; F Cabanillas; D Klippensten; W Hiddemann; R Castellino; N L Harris; J O Armitage; W Carter; R Hoppe; G P Canellos Journal: J Clin Oncol Date: 1999-04 Impact factor: 44.544
Authors: Robert Z Orlowski; Thomas E Stinchcombe; Beverly S Mitchell; Thomas C Shea; Albert S Baldwin; Stephanie Stahl; Julian Adams; Dixie-Lee Esseltine; Peter J Elliott; Christine S Pien; Roberto Guerciolini; Jessica K Anderson; Natalie D Depcik-Smith; Rita Bhagat; Mary Jo Lehman; Steven C Novick; Owen A O'Connor; Steven L Soignet Journal: J Clin Oncol Date: 2002-11-15 Impact factor: 44.544
Authors: A Belch; C T Kouroukis; M Crump; L Sehn; R D Gascoyne; R Klasa; J Powers; J Wright; E A Eisenhauer Journal: Ann Oncol Date: 2006-09-13 Impact factor: 32.976
Authors: Paul G Richardson; Hannah Briemberg; Sundar Jagannath; Patrick Y Wen; Bart Barlogie; James Berenson; Seema Singhal; David S Siegel; David Irwin; Michael Schuster; Gordan Srkalovic; Raymond Alexanian; S Vincent Rajkumar; Steven Limentani; Melissa Alsina; Robert Z Orlowski; Kevin Najarian; Dixie Esseltine; Kenneth C Anderson; Anthony A Amato Journal: J Clin Oncol Date: 2006-06-05 Impact factor: 44.544
Authors: Owen A O'Connor; John Wright; Craig Moskowitz; Jamie Muzzy; Barbara MacGregor-Cortelli; Michael Stubblefield; David Straus; Carol Portlock; Paul Hamlin; Elizabeth Choi; Otila Dumetrescu; Dixie Esseltine; Elizabeth Trehu; Julian Adams; David Schenkein; Andrew D Zelenetz Journal: J Clin Oncol Date: 2004-12-21 Impact factor: 44.544
Authors: Andre Goy; Anas Younes; Peter McLaughlin; Barbara Pro; Jorge E Romaguera; Frederick Hagemeister; Luis Fayad; Nam H Dang; Felipe Samaniego; Michael Wang; Kristine Broglio; Barry Samuels; Frederic Gilles; Andreas H Sarris; Susan Hart; Elizabeth Trehu; David Schenkein; Fernando Cabanillas; Alma M Rodriguez Journal: J Clin Oncol Date: 2004-12-21 Impact factor: 44.544
Authors: Martin Dreyling; Georg Lenz; Eva Hoster; Achiel Van Hoof; Christian Gisselbrecht; Rudolf Schmits; Bernd Metzner; Lorenz Truemper; Marcel Reiser; Hjalmar Steinhauer; Jean-Michel Boiron; Marc A Boogaerts; Ali Aldaoud; Vittorio Silingardi; Hanneke C Kluin-Nelemans; Joerg Hasford; Reza Parwaresch; Michael Unterhalt; Wolfgang Hiddemann Journal: Blood Date: 2004-12-09 Impact factor: 22.113
Authors: Sandra J Strauss; Lenushka Maharaj; Susan Hoare; Peter W Johnson; John A Radford; Sarah Vinnecombe; Lynda Millard; Ama Rohatiner; Anthony Boral; Elizabeth Trehu; David Schenkein; Frances Balkwill; Simon P Joel; T Andrew Lister Journal: J Clin Oncol Date: 2006-04-10 Impact factor: 44.544
Authors: Shruti Desai; Michelle Maurin; Matthew A Smith; Sophia C E Bolick; Sophie Dessureault; Jianguo Tao; Eduardo Sotomayor; Kenneth L Wright Journal: Mol Cancer Res Date: 2010-06-08 Impact factor: 5.852
Authors: Hongtao Liu; Jeffrey L Johnson; Greg Koval; Greg Malnassy; Dorie Sher; Lloyd E Damon; Eric D Hsi; Donna Marie Bucci; Charles A Linker; Bruce D Cheson; Wendy Stock Journal: Haematologica Date: 2011-11-18 Impact factor: 9.941
Authors: Nishitha Reddy; John P Greer; Stacey Goodman; Adetola Kassim; David S Morgan; Wichai Chinratanalab; Stephen Brandt; Brian Englehardt; Olalekan Oluwole; Madan H Jagasia; Bipin N Savani Journal: Exp Hematol Date: 2012-01-21 Impact factor: 3.084
Authors: Robert A Baiocchi; Lapo Alinari; Mark E Lustberg; Thomas S Lin; Pierluigi Porcu; Xiaobai Li; Jeffrey S Johnston; John C Byrd; Kristie A Blum Journal: Cancer Date: 2010-12-14 Impact factor: 6.860